Format

Send to

Choose Destination
Cancer Chemother Pharmacol. 2017 Oct;80(4):799-805. doi: 10.1007/s00280-017-3421-7. Epub 2017 Sep 7.

Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea.

Author information

1
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea.
2
Department of Internal Medicine, Gachon University, Gil Medical Center, Incheon, South Korea.
3
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.
4
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
5
Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
6
Department of Internal Medicine, Inha University College of Medicine, Incheon, South Korea.
7
Center for Liver Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, 10408, South Korea.
8
Department of Internal Medicine, Soon Chun Hyang University Cheonan Hospital, Soon Chun Hyang University College of Medicine, Cheonan, South Korea.
9
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea. yongtkim@snu.ac.kr.
10
Center for Liver Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, 10408, South Korea. lwj@ncc.re.kr.

Abstract

PURPOSE:

Everolimus is a standard treatment option for advanced pancreatic neuroendocrine tumors (pNETs). This multicenter study evaluated the efficacy and safety of everolimus in low and intermediate grade advanced pNETs.

METHODS:

Tumors were graded according to the World Health Organization 2010 classification system. Patients with low or intermediate grade pNETs who received everolimus as first- or second-line chemotherapy between 2002 and 2014 were included.

RESULTS:

A total of 40 patients with metastatic or recurrent pNETs were included in this study. The median age was 54.5 years (range 19-83 years). Twelve patients (30%) experienced recurrence. There were 11 patients (27.5%) with low grade pNETs and 29 (72.5%) with intermediate. Everolimus was administered as first-line therapy in 30 patients (75%) and as second-line therapy in 10 patients (25%). The median progression-free survival (PFS) of patients with low and intermediate grade pNETs was significantly different (median not reached vs. 11 months, P = 0.015). On multivariate analysis, tumor grade (intermediate grade; HR 6.52, 95% CI 1.31-32.27, P = 0.022) was the only independent prognostic factor for PFS in pNETs. The most common adverse events were stomatitis, skin rash, and anemia.

CONCLUSIONS:

World Health Organization 2010 grade is the most important determinant for PFS in patients undergoing everolimus treatment for pNETs with an acceptable incidence of adverse events.

KEYWORDS:

Everolimus; Pancreatic neuroendocrine tumor; Prognosis; Tumor grade; World Health Organization classification

PMID:
28884280
DOI:
10.1007/s00280-017-3421-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center